Table of Contents

Preface.

1. Concepts.

1.1 Introduction.

1.2 Cost-effectiveness data and the parameters of interest.

1.3 The cost-effectiveness plane, the ICER and INB.

1.4 Outline.

2. Parameter Estimation for Non-censored Data.

2.1 Introduction.

2.2 Cost.

2.3 Effectiveness.

2.4 Summary.

3. Parameter Estimation for Censored Data.

3.1 Introduction.

3.2 Mean Cost.

3.3 Effectiveness.

3.4 Summary.

4. Cost-effectiveness Analysis.

4.1 Introduction.

4.2 Incremental cost-effectiveness ratio.

4.3 Incremental net benefit.

4.4 The cost-effectiveness acceptability curve.

4.5 Using bootstrap methods.

4.6 A Bayesian incremental net benefit approach.

4.7 Kinked thresholds.

4.8 Summary.

5. Cost-effectiveness Analysis: Examples.

5.1 Introduction.

5.2 The CADET-Hp trial.

5.3 Symptomatic hormone-resistant prostate cancer.

5.4 The Canadian implantable defibrillator study (CIDS).

5.5 The EVALUATE trial.

5.6 Bayesian approach applied to the UK PDS study.

5.7 Summary.

6. Power and Sample Size Determination.

6.1 Introduction.

6.2 Approaches based on the cost-effectiveness plane.

6.3 The classical approach based on net benefit.

6.4 Bayesian take on the classical approach.

6.5 The value of information approach.

6.6 Summary.

7. Covariate Adjustment and Sub-group Analysis.

7.1 Introduction.

7.2 Non-censored data.

7.3 Censored data.

7.4 Summary.

8. Multicenter and Multinational Trials.

8.1 Introduction.

8.2 Background to multinational cost-effectiveness.

8.3 Fixed effect approaches.

8.4 Random effects approaches.  

8.5 Summary.

9. Modeling Cost-effectiveness.

9.1 Introduction.

9.2 A general framework for modeling cost-effectiveness results.

9.3 Case study: an economic appraisal of the goal study.  

9.4 Summary.

References.

Author Index.

Subject Index.

Series List.

About the Author

Dr.Andrew R. Willan is an academic biostatistician and clinical trial methodologist, and currently holds the positions of Senior Scientist Emeritus at SickKids Research Institute, Professor of Biostatistics in the Dalla Lana School of Public Health at the University of Toronto, and Professor Emeritus in the Department of Clinical Epidemiology and Biostatistics at McMaster University. His contributions to statistical methodology include publications in the areas of cost-effectiveness analysis, value of information methods, management trials, crossover trials, non-nested regression analysis and bivariate response models. Dr. Willan has been particularly instrumental in developing the field of statistical analysis of cost-effectiveness data with twenty peer-review articles and a book, co-authored with Professor Andy Briggs, in the Wiley Statistics in Practice series, entitled Statistical Analysis of Cost-effectiveness Data.

Reviews

"…Willan and Briggs have written a thorough, balanced, and useful book.  I look forward to reading an enlarged, revised second edition." (Journal of the American Statistical Association, June 2008) "Overall this is a useful book for this new discipline that helps considerably the reader to enter this topic and learn how to handle this type of problems." (Zentralblatt MATH 2008)